Emerging therapeutic approaches to mitochondrial diseases

Developmental Disabilities Research Reviews

Volumn 16, Issue 2, 2010, Pages 219-229

  Wenz, Tina ^a,b   Williams, Sion L ^a   Bacman, Sandra R ^a   Moraes, Carlos T ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Gene therapy; Heteroplasmy; Mitochondrial diseases; Oxidative phosphorylation defects

Indexed keywords

CELL NUCLEUS DNA; IDEBENONE; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; QUINONE DERIVATIVE; ROTENONE; TRANSFER RNA; UBIDECARENONE;

ALLOGENEIC STEM CELL TRANSPLANTATION; BIOGENESIS; CELL TRANSFER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HETEROPLASMY; HUMAN; KETOGENIC DIET; MITOCHONDRIAL DNA DEPLETION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN TRANSPORT; REVIEW; RNA STABILITY; SATELLITE CELL; THROMBOCYTE TRANSFUSION;

EID: 77956246418     PISSN: 19405510     EISSN: 10982779     Source Type: Journal    
DOI: 10.1002/ddrr.109     Document Type: Review

References (127)

1. Abu-Gosh SE, Kolvazon N, Tirosh B, et al. 2009. Multiple triphenylphosphonium cations shuttle a hydrophilic peptide into mitochondria. Mol Pharm 6:1138-1144.
2. Acin-Perez R, Salazar E, Brosel S, et al. 2009a. Modulation of mitochondrial protein phosphorylation by soluble adenylyl cyclase ameliorates cytochrome oxidase defects. EMBO Mol Med 1(8-9):392-406.
3. Acin-Perez R, Salazar E, Kamenetsky M et al. 2009b. Cyclic AMP produced inside mitochondria regulates oxidative phosphorylation. Cell Metab 9:265-276.
4. Adlam VJ, Harrison JC, Porteous CM, et al. 2005. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J 19:1088-1095.
5. Ahola-Erkkila S, Carroll CJ, Peltola-Mjosund K, et al. 2010. Ketogenic diet slows down mitochondrial myopathy progression in mice. Hum Mol Genet 19:1974-1984.
6. Alexeyev MF, Venediktova N, Pastukh V, et al. 2008. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes. Gene Ther 15:516-523.
7. Andrews RM, Griffiths PG, Chinnery PF, et al. 1999. Evaluation of bupivacaine-induced muscle regeneration in the treatment of ptosis in patients with chronic progressive external ophthalmoplegia and Kearns-Sayre syndrome. Eye (Lond) 13(Part 6):769-772.
8. Artuch R, Aracil A, Mas A, et al. 2004. Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients. Neuropediatrics 35:95-98. (Pubitemid 38639315)
9. Bacman SR, Williams SL, Garcia S, et al. 2010. Organ-specific shifts in mtDNA heteroplasmy following systemic delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 17:713-720.
10. Bacman SR, Williams SL, Hernandez D, et al. 2007. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a 'differential multiple cleavage-site' model. Gene Ther 14:1309-1318.
11. Balaban RS, Nemoto S, Finkel T. 2005. Mitochondria, oxidants, and aging. Cell 120:483-495.
12. Barber-Singh J, Seo BB, Nakamaru-Ogiso E, et al. 2009. Neuroprotective effect of longterm NDI1 gene expression in a chronic mouse model of Parkinson disorder. Rejuvenation Res 12:259-267.
13. Barbiroli B, Frassineti C, Martinelli P, et al. 1997. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol Biol (Noisy-le-grand) 43:741-749.
14. Bastin J, Aubey F, Rotig A, et al. 2008. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. J Clin Endocrinol Metab 93:1433-1441.
15. Bayona-Bafaluy MP, Blits B, Battersby BJ, et al. 2005. Rapid directional shift of mitochondrial DNA heteroplasmy in animal tissues by a mitochondrially targeted restriction endonuclease. Proc Natl Acad Sci USA 102:14392-14397.
16. Becker-Hapak M, McAllister SS, Dowdy SF. 2001. TAT-mediated protein transduction into mammalian cells. Methods 24:247-256. (Pubitemid 32846431)
17. Benton CR, Wright DC, Bonen A. 2008. PGC-1alpha-mediated regulation of gene expression and metabolism: implications for nutrition and exercise prescriptions. Appl Physiol Nutr Metab 33:843-862.
18. Bonnet C, Augustin S, Ellouze S, et al. 2008. The optimized allotopic expression of ND1 or ND4 genes restores respiratory chain complex I activity in fibroblasts harboring mutations in these genes. Biochim Biophys Acta 1783:1707-1717.
19. Brini M, Pinton P, King MP, et al. 1999. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 5:951-954.
20. Brown DT, Herbert M, Lamb VK, et al. 2006. Transmission of mitochondrial DNA disorders: possibilities for the future. Lancet 368:87-89.
21. Brown SE, Ross MF, Sanjuan-Pla A, et al. 2007. Targeting lipoic acid to mitochondria: synthesis and characterization of a triphenylphosphonium- conjugated alpha-lipoyl derivative. Free Radic Biol Med 42:1766-1780. (Pubitemid 46759581)
22. Carroll D. 2008. Progress and prospects: zinc-finger nucleases as gene therapy agents. Gene Ther 15:1463-1468.
23. Chinnery PF, Taylor RW, Diekert K, et al. 2000. Peptide nucleic acid and delivery to human mitochondria. Gene Ther 7:813.
24. Clark KM, Bindoff LA, Lightowlers RN, et al. 1997. Reversal of a mitochondrial DNA defect in human skeletal muscle. Nat Genet 16:222-224.
25. Cocheme HM, Kelso GF, James AM, et al. 2007. Mitochondrial targeting of quinones: therapeutic implications. Mitochondrion 7 (Suppl): S94-S102.
26. Cohen J, Scott R, Schimmel T, et al. 1997. Birth of infant after transfer of anucleate donor oocyte cytoplasm into recipient eggs. Lancet 350:186-187. (Pubitemid 27303631)
27. Cree LM, Samuels DC, Chinnery PF. 2009. The inheritance of pathogenic mitochondrial DNA mutations. Biochim Biophys Acta 1792:1097-1102.
28. Dassa EP, Dufour E, Goncalves S, et al. 2009a. The alternative oxidase, a tool for compensating cytochrome c oxidase deficiency in human cells. Physiol Plant 137:427-434.
29. Dassa EP, Dufour E, Goncalves S, et al. 2009b. Expression of the alternative oxidase complements cytochrome c oxidase deficiency in human cells. EMBO Mol Med 1:30-36.
30. DeCorby A, Gaskova D, Sayles LC, et al. 2007. Expression of Ndi1p, an alternative NADH: ubiquinone oxidoreductase, increases mitochondrial membrane potential in a C. elegans model of mitochondrial disease. Biochim Biophys Acta 1767:1157-1163.
31. Del Gaizo V, MacKenzie JA, Payne RM. 2003. Targeting proteins to mitochondria using TAT. Mol Genet Metab 80(1-2):170-180. (Pubitemid 37272243)
32. Del Gaizo V, Payne RM. 2003. A novel TAT-mitochondrial signal sequence fusion protein is processed, stays in mitochondria, and crosses the placenta. Mol Ther 7:720-730.
33. Di Giovanni S, Mirabella M, Spinazzola A, et al. 2001. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 57:515-518.
34. Dimauro S, Rustin P. 2009. A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases. Biochim Biophys Acta 1792:1159-1167.
35. DiMauro S, Schon EA. 2003. Mitochondrial respiratory-chain diseases. N Engl J Med 348:2656-2668.
36. Dong W, Gao D, Zhang X. 2007. Mitochondria biogenesis induced by resveratrol against brain ischemic stroke. Med Hypotheses 69:700-701. (Pubitemid 47043252)
37. Ellouze S, Augustin S, Bouaita A, et al. 2008. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 83:373-387.
38. Enriquez JA, Chomyn A, Attardi G. 1995. MtDNA mutation in MERRF syndrome causes defective aminoacylation of tRNA(Lys) and premature translation termination. Nat Genet 10:47-55.
39. Ernster L, Dallner G. 1995. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta 1271: 195-204.
40. Esposti MD, Ngo A, Ghelli A, et al. 1996. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys 33:395-400.
41. Fernandez-Ayala DJ, Sanz A, Vartiainen S, et al. 2009. Expression of the Ciona intestinalis alternative oxidase (AOX) in Drosophila complements defects in mitochondrial oxidative phosphorylation. Cell Metab 9:449-460.
42. Finkel T. 2005. Radical medicine: treating ageing to cure disease. Nat Rev Mol Cell Biol 6:971-976.
43. Flierl A, Chen Y, Coskun PE, et al. 2005. Adeno-associated virus-mediated gene transfer of the heart/muscle adenine nucleotide translocator (ANT) in mouse. Gene Ther 12:570-578. (Pubitemid 40468104)
44. Fulka J Jr, Fulka H, John JC. 2007. Transmission of mitochondrial DNA disorders: possibilities for the elimination of mutated mitochondria. Cloning Stem Cells 9:47-50.
45. Graham BH, Waymire KG, Cottrell B, et al. 1997. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat Genet 16:226-234.
46. Gray RE, Law RH, Devenish RJ, et al. 1996. Allotopic expression of mitochondrial ATP synthase genes in nucleus of Saccharomyces cerevisiae. Methods Enzymol 264:369-389.
47. Guy J, Qi X, Koilkonda RD, et al. 2009. Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci 50:4205-4214.
48. Haas RH. 2007. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 7 (Suppl):S136-S145.
49. Hakkaart GA, Dassa EP, Jacobs HT, et al. 2006. Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration. EMBO Rep 7:341-345.
50. Haller RG, Vissing J. 2009. Drilling for energy in mitochondrial disease. Arch Neurol 66:931-932.
51. Hawke TJ, Garry DJ. 2001. Myogenic satellite cells: physiology to molecular biology. J Appl Physiol 91:534-551.
52. Hirano M, Marti R, Casali C, et al. 2006. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 67:1458-1460.
53. Iyer S, Thomas RR, Portell FR, et al. 2009. Recombinant mitochondrial transcription factor A with N-terminal mitochondrial transduction domain increases respiration and mitochondrial gene expression. Mitochondrion 9:196-203.
54. James AM, Blaikie FH, Smith RA, et al. 2003. Specific targeting of a DNA-alkylating reagent to mitochondria. Synthesis and characterization of [4-((11aS)-7-methoxy-1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4] benzodiaze pin-5-on-8-oxy)butyl]-triphenylphosphonium iodide. Eur J Biochem 270:2827-2836.
55. James AM, Cocheme HM, Smith RA, et al. 2005. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem 280:21295-21312.
56. Jenuth JP, Peterson AC, Shoubridge EA. 1997. Tissue-specific selection for different mtDNA genotypes in heteroplasmic mice. Nat Genet 16:93-95.
57. Kang HC, Lee YM, Kim HD, et al. 2007. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 48:82-88.
58. Keeney PM, Quigley CK, Dunham LD, et al. 2009. Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 20:897-907.
59. Klug A. 2010. The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem 79:213-231.
60. Kolesnikova OA, Entelis NS, Jacquin-Becker C, et al. 2004. Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells. Hum Mol Genet 13:2519-2534.
61. Kuehn BM. 2009. Scientists probe method to prevent inherited mitochondrial gene diseases. JAMA 302:1409.
62. Kyriakouli DS, Boesch P, Taylor RW, et al. 2008. Progress and prospects: gene therapy for mitochondrial DNA disease. Gene Ther 15:1017-1023. (Pubitemid 351927692)
63. Lara MC, Weiss B, Illa I, et al. 2006. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 67:1461-1463.
64. Li R, Guan MX. 2010. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNA-Leu(UUR) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol Cell Biol 30:2147-2154.
65. Ling J, Roy H, Qin D, et al. 2007. Pathogenic mechanism of a human mitochondrial tRNAPhe mutation associated with myoclonic epilepsy with ragged red fibers syndrome. Proc Natl Acad Sci USA 104:15299-15304.
66. Maalouf M, Sullivan PG, Davis L, et al. 2007. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience 145:256-264. (Pubitemid 46227735)
67. Mahata B, Mukherjee S, Mishra S, et al. 2006. Functional delivery of a cytosolic tRNA into mutant mitochondria of human cells. Science 314:471-474.
68. Mancuso M, Coppede F, Migliore L, et al. 2006. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis 10:59-73.
69. Manfredi G, Fu J, Ojaimi J, et al. 2002. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nat Genet 30:394-399.
70. Marella M, Seo BB, Nakamaru-Ogiso E, et al. 2008. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS One 3:e1433. (Pubitemid 351248278)
71. Meier T, Buyse G. 2009. Idebenone: an emerging therapy for Friedreich ataxia. J Neurol 256(Suppl 1):25-30.
72. Minczuk M, Kolasinska-Zwierz P, Murphy MP, et al. 2010. Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA. Nat Protoc 5:342-356.
73. Minczuk M, Papworth MA, Kolasinska P, et al. 2006. Sequence-specific modification of mitochondrial DNA using a chimeric zinc finger methylase. Proc Natl Acad Sci USA 103:19689-19694.
74. Minczuk M, Papworth MA, Miller JC, et al. 2008. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res 36:3926-3938.
75. Morgan JE, Partridge TA. 2003. Muscle satellite cells. Int J Biochem Cell Biol 35:1151-1156.
76. Mori T, Kagatsume I, Shinomiya K, et al. 2009. Sandwiched zinc-finger nucleases harboring a single-chain FokI dimer as a DNA-cleavage domain. Biochem Biophys Res Commun 390:694-697.
77. Mukherjee S, Mahata B, Mahato B, et al. 2008. Targeted mRNA degradation by complex-mediated delivery of antisense RNAs to intracellular human mitochondria. Hum Mol Genet 17:1292-1298. (Pubitemid 351566965)
78. Murphy JL, Blakely EL, Schaefer AM, et al. 2008. Resistance training in patients with single, large-scale deletions of mitochondrial DNA. Brain 131(Part 11):2832-2840.
79. Murphy MP, Smith RA. 2000. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv Drug Deliv Rev 41:235-250.
80. Nitta A, Murakami Y, Furukawa Y, et al. 1994. Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol 349:401-407.
81. Noh HS, Kim YS, Choi WS. 2008. Neuroprotective effects of the ketogenic diet. Epilepsia 49(Suppl 8):120-123.
82. Oca-Cossio J, Kenyon L, Hao H, et al. 2003. Limitations of allotopic expression of mitochondrial genes in mammalian cells. Genetics 165:707-720.
83. Ojuka EO. 2004. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc Nutr Soc 63:275-278.
84. Park H, Davidson E, King MP. 2003. The pathogenic A3243G mutation in human mitochondrial tRNALeu(UUR) decreases the efficiency of aminoacylation. Biochemistry 42:958-964.
85. Park H, Davidson E, King MP. 2008. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. RNA 14:2407-2416.
86. Park JS, Li YF, Bai Y. 2007. Yeast NDI1 improves oxidative phosphorylation capacity and increases protection against oxidative stress and cell death in cells carrying a Leber's hereditary optic neuropathy mutation. Biochim Biophys Acta 1772:533-542.
87. Perales-Clemente E, Bayona-Bafaluy MP, Perez-Martos A, et al. 2008. Restoration of electron transport without proton pumping in mammalian mitochondria. Proc Natl Acad Sci USA 105:18735-18739.
88. Perez EE, Wang J, Miller JC, et al. 2008. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26:808-816.
89. Rapoport M, Saada A, Elpeleg O, et al. 2008. TAT-mediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther 16:691-697. (Pubitemid 351426170)
90. Rego AC, Oliveira CR. 2003. Mitochondrial dysfunction and reactive oxygen species in excitotoxicity and apoptosis: implications for the pathogenesis of neurodegenerative diseases. Neurochem Res 28:1563-1574.
91. Rodriguez-Cuenca S, Cocheme HM, Logan A, et al. 2010. Consequences of long-term oral administration of the mitochondria-targeted antioxidant MitoQ to wild-type mice. Free Radic Biol Med 48:161-172.
92. Ross CM. 2005. Folate, mitochondria. ROS, and the aging brain. Am J Med 118:1174; author reply 1174-1175.
93. Rustin P, Jacobs HT. 2009. Respiratory chain alternative enzymes as tools to better understand and counteract respiratory chain deficiencies in human cells and animals. Physiol Plant 137:362-370.
94. Santra S, Gilkerson RW, Davidson M, et al. 2004. Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells. Ann Neurol 56:662-669.
95. Sasarman F, Antonicka H, Shoubridge EA. 2008. The A3243G tRNALeu(UUR) MELAS mutation causes amino acid misincorporation and a combined respiratory chain assembly defect partially suppressed by overexpression of EFTu and EFG2. Hum Mol Genet 17:3697-3707.
96. Scarpulla RC. 2008. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev 88:611-638. (Pubitemid 351520089)
97. Schaefer AM, Taylor RW, Turnbull DM, et al. 2004. The epidemiology of mitochondrial disorders - past, present and future. Biochim Biophys Acta 1659(2-3):115-120.
98. Schulz JB, Di Prospero NA, Fischbeck K. 2009. Clinical experience with high-dose idebenone in Friedreich ataxia. J Neurol 256 (Suppl 1):42-45.
99. Seo BB, Marella M, Yagi T, et al. 2006. The single subunit NADH dehydrogenase reduces generation of reactive oxygen species from complex I. FEBS Lett 580:6105-6108.
100. Seo BB, Nakamaru-Ogiso E, Flotte TR, et al. 2002. A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. Mol Ther 6:336-341.
101. Sgarbi G, Casalena GA, Baracca A, et al. 2009. Human NARP mitochondrial mutation metabolism corrected with alpha-ketoglutarate/aspartate: a potential new therapy. Arch Neurol 66:951-957.
102. Siedow JN, Umbach AL. 2000. The mitochondrial cyanide-resistant oxidase: structural conservation amid regulatory diversity. Biochim Biophys Acta 1459(2-3):432-439.
103. Smith RA, Porteous CM, Gane AM et al. 2003. Delivery of bioactive molecules to mitochondria in vivo. Proc Natl Acad Sci USA 100:5407-5412.
104. Srivastava S, Diaz F, Iommarini L, et al. 2009. PGC- 1alpha/beta induced expression partially compensates for respiratory chain defects in cells from patients with mitochondrial disorders. Hum Mol Genet 18:1805-1812.
105. Srivastava S, Moraes CT. 2001. Manipulating mitochondrial DNA heteroplasmy by a mitochondrially targeted restriction endonuclease. Hum Mol Genet 10:3093-3099. (Pubitemid 34083495)
106. Sylvestre J, Margeot A, Jacq C, et al. 2003. The role of the 3′ untranslated region in mRNA sorting to the vicinity of mitochondria is conserved from yeast to human cells. Mol Biol Cell 14:3848-3856.
107. Tachibana M, Sparman M, Sritanaudomchai H, et al. 2009. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 461:367-372.
108. Taivassalo T, Haller RG. 2004. Implications of exercise training in mtDNA defects - use it or lose it? Biochim Biophys Acta 1659(2-3):221-231.
109. Taivassalo T, Haller RG. 2005. Exercise and training in mitochondrial myopathies. Med Sci Sports Exerc 37:2094-2101.
110. Tanaka M, Borgeld HJ, Zhang J, et al. 2002. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J Biomed Sci 9(6 Part 1):534-541.
111. Tarassov I, Kamenski P, Kolesnikova O, et al. 2007. Import of nuclear DNA-encoded RNAs into mitochondria and mitochondrial translation. Cell Cycle 6:2473-2477.
112. Taylor RW, Chinnery PF, Turnbull DM, et al. 1997. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nat Genet 15:212-215.
113. Thorburn DR, Dahl HH. 2001. Mitochondrial disorders: genetics, counseling, prenatal diagnosis and reproductive options. Am J Med Genet 106:102-114. (Pubitemid 32601622)
114. Toro A, Grunebaum E. 2006. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest 116:2717-2726.
115. Urnov FD, Miller JC, Lee YL, et al. 2005. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 435:646-651.
116. Visch HJ, Rutter GA, Koopman WJ, et al. 2004. Inhibition of mitochondrial Na+-Ca2+ exchange restores agonist-induced ATP production and Ca2+ handling in human complex I deficiency. J Biol Chem 279:40328-40336.
117. Vocero-Akbani A, Chellaiah MA, Hruska KA, et al. 2001. Protein transduction: delivery of Tat-GTPase fusion proteins into mammalian cells. Methods Enzymol 332:36-49.
118. Vyas PM, Payne RM. 2008. TAT opens the door. Mol Ther 16:647-648.
119. Wagstaff KM, Jans DA. 2006. Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem 13:1371-1387.
120. Walia A, Thapa BR, Kim V. 2006. Mitochondrial neuro-gastrointestinal encephalopathy syndrome. Indian J Pediatr 73:1112-1114.
121. Warner A, Vaziri ND. 1981. Treatment of lactic acidosis. South Med J 74:841-847.
122. Wenz T. 2009. PGC-1alpha activation as a therapeutic approach in mitochondrial disease. IUBMB Life 61:1051-1062.
123. Wenz T, Diaz F, Hernandez D, et al. 2009. Endurance exercise is protective for mice with mitochondrial myopathy. J Appl Physiol 106:1712-1719.
124. Wenz T, Diaz F, Spiegelman BM, et al. 2008. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 8:249-256.
125. Wu H, Kanatous SB, Thurmond FA, et al. 2002. Regulation of mitochondrial biogenesis in skeletal muscle by CaMK. Science 296:349-352.
126. Wu Z, Huang X, Feng Y, et al. 2006. Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. Proc Natl Acad Sci USA 103:14379-14384.
127. Yamada Y, Akita H, Kogure K, et al. 2007. Mitochondrial drug delivery and mitochondrial disease therapy - an approach to liposome-based delivery targeted to mitochondria. Mitochondrion 7(1-2):63-71. (Pubitemid 46351977)